Viral InfectionsBacterial InfectionsFungal InfectionsMixed InfectionMycobacterium InfectionInfection of Uncertain AetiologyPneumoniaSepsis
Investigational drug(s) / intervention(s)
Biomarker blood draw and saliva collection
Biomarker blood draw and saliva collection: Three peripheral 10 - 20mL blood sample (if available) Three 1 - 5mL salivary samples (if available)
Study summary
Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID).
Phase 1
1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2
2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics
Eligibility
Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion Criteria:
Patients eligible for enrolment include:
With reference to previous inclusion criteria are:
* Adults ≥18 years of age; AND
* Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)\*; AND
* Informed consent.
Note: scaRID is defined according to ALL three criteria:
1. Community acquired (not hospitalised for \<28 days); AND
2. Acute infection (defined as symptom onset \<8 days and any ONE of reported fever or chills or aural temperature \>37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND
3. Probable respiratory infection - According to any ONE of:
1. new cough or new sputum production or
2. chest pain or
3. dyspnoea or
4. tachypnoea or
5. abnormal lung examination or
6. respiratory failure; or
7. physician's judgment (presenting with systemic or gastrointestinal symptoms).
Control subjects will be drawn from two groups:
* The worried well - adult patients with a National Early Warning Score (NEWS) \<3 and a temperature \<37.5°C.
* Relatives or accompanying friends with no acute illness.
Exclusion Criteria:
* Refusal of consent;
* Recent hospitalisation (\<28 days);
* Enrolled in another clinical trial
* Cellulitis;
* Skin or orthopaedic infections;
* Urinary tract infection;
* Acute abdominal sepsis;
* Sexual transmitted disease;
* Human immunodeficiency virus (HIV) infection;
* Immunocompromised/potential neutropenic fever;
* Solid organ or haematopoietic stem-cell transplant within the previous 90 days;
* Active graft-versus-host disease or bronchiolitis obliterans;
* Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases;
* Stroke;
* Toxidrome;
* Non-organic acute psychosis.
Primary outcome measure(s)
WHO-CPS — Up to 30 days Differentiation of WHO-CPS \>6 from WHO-CPS ≤6
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.